New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2013
14:04 EDTPSTIPluristem Therapeutics receives FDA orphan drug designation
Pluristem Therapeutics received FDA orphan drug designation for allogeneic ex-vivo expanded placental adherent stromal cells. Reference Link
News For PSTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
05:09 EDTPSTIPluristem moves to large-scale manufacturing after second product line completed
Pluristem Therapeutics announced that it has completed development of its second major product line, and can now begin manufacturing the cells on a large-scale at its state-of-the art facility in order to meet demand for anticipated studies in a range of hematologic conditions. This second cell product candidate, called PLX-RAD, was created using Pluristem's proprietary three dimensional cell expansion technology platform. The company's first product, PLX-PAD, is already in clinical trials for the treatment of peripheral artery disease, muscle injury and pulmonary arterial hypertension. Pluristem's development plan for the PLX-RAD cells considers numerous potential clinical indications such as: enhancement of engraftment of transplanted hematopoietic stem cells for the treatment of bone marrow deficiency, which can result from immune system disorders, genetic diseases, and treatment of leukemia and other blood cancers; treatment of bone marrow deficiency in patients who have undergone chemotherapy; treatment of acute radiation syndrome, or ARS in conjunction with the U.S. National Institutes of Health's National Institute of Allergy and Infectious Diseases.
October 20, 2014
07:19 EDTPSTIIBC Life Sciences to hold a conference
Subscribe for More Information
October 14, 2014
16:42 EDTPSTIPluristem Therapeutics files $200M mixed securities shelf

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use